UroGen Pharma URGN Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's accretion (amortization) of discounts and premiums, investments?
- UroGen Pharma (URGN) reported accretion (amortization) of discounts and premiums, investments of -$26K in Q1 2026.
- How has UroGen Pharma's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- UroGen Pharma's accretion (amortization) of discounts and premiums, investments decreased by 103.4% year-over-year, from $774K to -$26K.
- What is the long-term trend for UroGen Pharma's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), UroGen Pharma's accretion (amortization) of discounts and premiums, investments has grown at a 40.1% compound annual growth rate (CAGR), from -$486K to $1.88M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Reflects the non-cash adjustment to the carrying value of investment securities resulting from the amortization of premiums or the accretion of discounts. This adjustment aligns the book value of the investment portfolio with its effective interest rate over the holding period.